GANX
What one share of Gain Therapeutics holds
Pharmaceutical Preparations
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
Gain Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.51 |
|---|---|
| Cash and investments | $0.30 |
| Debt | $0.01 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$1.33 | $0.01 | −$1.22 | — | $1.75 |
| 2021 | $0.02 | −$1.37 | $0.01 | −$1.23 | — | $2.93 |
| 2022 | $0.01 | −$1.48 | $0.01 | −$1.25 | — | $1.59 |
| 2023 | $0.00 | −$1.71 | $0.00 | −$1.45 | — | $0.78 |
| 2024 | — | −$0.89 | $0.00 | −$0.83 | — | $0.27 |
| 2025 | — | −$0.61 | — | −$0.56 | — | $0.44 |